Foghorn Therapeutics (FHTX) Non-Current Debt (2019 - 2020)
Foghorn Therapeutics (FHTX) recorded quarterly Non-Current Debt of $19.7 million in Q4 2020, up 123.32% quarter-over-quarter from $8.8 million in Q3 2020, and up 79.32% on a YoY basis from $11.0 million in Q1 2020.
Foghorn Therapeutics (FHTX) Non-Current Debt (2019 - 2020) Analysis & Trends
Foghorn Therapeutics' Non-Current Debt history runs 2 years deep, the most recent figure standing at $19.7 million for Q4 2020.
- In Q4 2020, Non-Current Debt rose 79.32% year-over-year to $19.7 million; the TTM figure through Dec 2020 stood at $19.7 million (up 79.32% YoY), while the FY2020 annual figure was $19.7 million, up 79.32% from the prior year.
- Non-Current Debt was $19.7 million for Q4 2020 at Foghorn Therapeutics, up from $8.8 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $19.7 million in Q4 2020 to a low of $8.8 million in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 319.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Foghorn Therapeutics | 282.33 Mn | 193.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 19.65 Mn |
| Dec 31, 2020 | 19.65 Mn |
| Sep 30, 2020 | 8.80 Mn |
| Sep 30, 2020 | 8.80 Mn |
| Dec 31, 2019 | 10.96 Mn |
| Dec 31, 2019 | 10.96 Mn |